Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenoviridae Infections × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 397 Melanoma 256 Squamous Cell Carcinoma of Head and Neck 198 Parkinson Disease 4, Autosomal Dominant Lewy Body 164 Neoplasms 155 Breast Neoplasms 145 Triple Negative Breast Neoplasms 141 Neoplasm Metastasis 134 Colorectal Neoplasms 127 Lung Neoplasms 126 Carcinoma, Renal Cell 114 Head and Neck Neoplasms 103 Ovarian Neoplasms 94 Stomach Neoplasms 90 Carcinoma, Transitional Cell 76 Pancreatic Neoplasms 72 Urinary Bladder Neoplasms 70 Carcinoma, Hepatocellular 64 Endometrial Neoplasms 62 Uterine Cervical Neoplasms 57 Esophageal Neoplasms 53 Recurrence 46 Prostatic Neoplasms 44 Carcinoma 39 Glioblastoma 37 Sarcoma 36 Carcinoma, Squamous Cell 36 Small Cell Lung Carcinoma 32 Lymphoma 32 Fallopian Tube Neoplasms 32

Interventions

Gemcitabine 2 Cell Count 2 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 atezolizumab 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Radiotherapy 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Genetic Engineering 1 Endostatins 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡